tozuleristide

DRUG4 trials

Sponsors

Blaze Bioscience Inc., John Yu, University of Washington

Conditions

Central Nervous System TumorOral Cavity Squamous Cell CarcinomaPediatric Central Nervous System TumorStage I Lip and Oral Cavity Cancer AJCC v8Stage II Lip and Oral Cavity Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage IVA Lip and Oral Cavity Cancer AJCC v8

Phase 1

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

TerminatedNCT05316688

University of WashingtonOral Cavity Squamous Cell Carcinoma, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8 +2

Start: 2024-04-17End: 2025-09-26Updated: 2026-02-25

Phase 2

Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery

CompletedNCT03579602

Blaze Bioscience Inc.Pediatric Central Nervous System Tumor

Start: 2018-11-26End: 2022-06-13Updated: 2024-06-27

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System

CompletedNCT04743310

John YuCentral Nervous System Tumor

Start: 2021-09-30End: 2025-03-06Updated: 2025-06-13

Unknown Phase

Expanded Access for BLZ-100 (Tozuleristide)

Blaze Bioscience Inc.

Updated: 2025-04-04

Related Papers

A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific Pediatric Neuro-oncology Consortium).

Journal of Clinical Oncology2020-05-2010 citations